| 000 | 01060 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250517200934.0 | ||
| 008 | ####s 0 0 eng d | ||
| 022 | _a1949-2553 | ||
| 024 | 7 |
_a10.18632/oncotarget.22332 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSwinnen, Lode J | |
| 245 | 0 | 0 |
_aPhase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). _h[electronic resource] |
| 260 |
_bOncotarget _cJan 2018 |
||
| 300 |
_a766-773 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 700 | 1 | _aO'Neill, Anne | |
| 700 | 1 | _aImus, Philip H | |
| 700 | 1 | _aGujar, Sachin | |
| 700 | 1 | _aSchiff, David | |
| 700 | 1 | _aKleinberg, Lawrence R | |
| 700 | 1 | _aAdvani, Ranjana H | |
| 700 | 1 | _aDunbar, Erin M | |
| 700 | 1 | _aMoore, Dennis | |
| 700 | 1 | _aGrossman, Stuart A | |
| 773 | 0 |
_tOncotarget _gvol. 9 _gno. 1 _gp. 766-773 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.18632/oncotarget.22332 _zAvailable from publisher's website |
| 999 |
_c28059672 _d28059672 |
||